Company: WHWK
Filing Date: 2025-03-31
Form Type: S-3
Source: 0001193125-25-068942
Chunk: 25

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-31
Form: S-3
Chunk 25
---
 been registered or qualified for sale or an exemption from registration or qualification
requirements is available and is complied with.

We have advised the selling stockholders that the anti-manipulation rules of Regulation M under the
Securities Exchange Act of 1934, as amended, may apply to sales of shares in the market and to the activities of the selling stockholders and their affiliates. In addition, to the extent applicable, we will make copies of this prospectus (as it may
be supplemented or amended from time to time) available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates
in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act.

We have agreed to
indemnify the selling stockholders against liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the shares offered by this prospectus.

We have agreed with the selling stockholders to use commercially reasonable efforts to cause the registration statement of which this prospectus constitutes a
part effective and to remain continuously effective until the earlier of (1) such time as all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with such registration statement or (2) the date
that all the shares covered by this prospectus cease to be “Registrable Securities” (as defined in the Registration Rights Agreement).

15

LEGAL MATTERS

The validity of the shares of our common stock being offered by this prospectus is being passed upon for us by Wilson Sonsini Goodrich & Rosati,
Professional Corporation, San Diego, California. Certain members of, and investment partnerships comprised of members of, and person associated with, Wilson Sonsini Goodrich & Rosati, Professional Corporation, directly or indirectly own
less than 0.1% of the outstanding shares of our common stock.

EXPERTS

The consolidated financial statements of Whitehawk Therapeutics, Inc as of December 31, 2023 and 2024, and for the years then ended incorporated by
reference in this prospectus and in the registration statement have been so incorporated in reliance on the report of BDO USA, P.C., an independent registered public accounting firm, given on the authority of said firm as experts in auditing and
accounting.

WHERE YOU CAN FIND ADDITIONAL INFORMATION

We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are